Day One Biopharmaceuticals filings document the company's transition from a Nasdaq-listed oncology biopharmaceutical issuer to an acquired company with Exchange Act deregistration filings. The record includes Form 25 removal of DAWN common stock from Nasdaq and Form 15 certification covering termination of registration or suspension of reporting duties after the acquisition.
Day One's 8-K filings report material agreements, tender-offer and merger-related events, shareholder voting and governance matters, capital-structure disclosures, and financial-statement exhibits. Other disclosures cover OJEMDA (tovorafenib), U.S. product revenue reporting, Ipsen's ex-U.S. commercialization rights, and clinical or regulatory updates for pediatric low-grade glioma and rare-cancer programs.
Day One Biopharmaceuticals, Inc. Schedule 13G/A amendment: Vestal Point Capital, LP (the Investment Manager) and Ryan Wilder file an amendment reporting 0% beneficial ownership of the issuer’s Common Stock as of 03/31/2026. The filing lists Vestal Point’s role as investment manager and Mr. Wilder’s roles and provides the reporting persons' business address.
Day One Biopharmaceuticals, Inc. Schedule 13G/A amendment shows a group of Atlas Venture entities collectively reporting zero beneficial ownership in the company’s common stock (CUSIP 23954D109). The filing lists multiple Atlas Venture partnerships and LLCs and is signed by Ommer Chohan on behalf of those entities.
Day One Biopharmaceuticals, Inc. large stockholder AI Day1 LLC and its affiliated reporting persons, including Len Blavatnik, have exited their position in the company. They tendered all shares into Servier Detroit Inc.’s cash tender offer at $21.50 per share, with pre-funded warrants converted into $21.4999 per warrant in cash. Following settlement on April 23, 2026, the group reports beneficial ownership of 0% of Day One’s common stock and confirms they ceased to be holders of more than five percent of the shares on that date.
Day One Biopharmaceuticals, Inc. insider entity AI Day1 LLC, a 10% owner, disposed of its entire position in connection with the company’s cash sale to Servier Detroit Inc. AI Day1 tendered 12,929,322 shares of Common Stock at $21.50 per share, all of which were accepted on April 23, 2026.
On the same date, each of AI Day1’s 827,586 pre-funded warrants to purchase Common Stock was converted into the right to receive $21.4999 in cash per warrant, leaving no remaining share or warrant holdings. The filing notes that these securities were held directly by AI Day1 and may be deemed beneficially owned by related Access Industries entities and Len Blavatnik, who each disclaim beneficial ownership beyond their pecuniary interest.
Day One Biopharmaceuticals, Inc. filed a Form 4 showing that Chief Executive Officer Jeremy Bender and related entities disposed of their equity in connection with the closing of the company’s cash merger with Servier. On April 23, 2026, each outstanding share of common stock was purchased or converted into the right to receive $21.50 per share in cash under the merger agreement. Various family trusts, including The Jeremy Bender 2023 Grantor Retained Annuity Trust and several Melissa Bender Grantor Retained Annuity Trusts, disposed of their Day One common shares to the issuer as part of the transaction. Bender’s directly held common stock, RSUs and stock options were also canceled and converted into cash based on the Merger Consideration, with options paid the difference between $21.50 and their exercise price. Following these issuer dispositions, the Form 4 shows zero shares and zero derivative awards remaining for the reported positions.
Day One Biopharmaceuticals executive Michael Vasconcelles disposed of all company equity holdings in connection with the closing of a cash merger. The filing shows that, upon the merger with Servier, each share of Common Stock was purchased or converted into the right to receive $21.50 in cash per share under the merger agreement.
Vasconcelles returned 4,397 Common shares to the issuer and all outstanding equity awards were canceled for cash. This included 106,875 and 226,000 Restricted Stock Units, and stock options for 171,000 and 346,000 shares with exercise prices of $11.16 and $6.64, respectively. Following these dispositions, his reported holdings in these securities are zero.
Day One Biopharmaceuticals’ COO and CFO, Charles N. York II, reported the cancellation of his equity due to the company’s merger with Servier. On April 23, 2026, each share of Day One common stock was cashed out at $21.50 per share under the merger terms.
York disposed of 312,025 shares of common stock in an issuer disposition, leaving him with zero reported common shares. His unvested stock options and restricted stock units first became fully vested and were then canceled at the merger’s effective time in exchange for cash equal to the merger consideration (or the merger price minus the option exercise price), less applicable taxes.
The filing shows multiple cancellations of RSUs and stock options covering hundreds of thousands of underlying shares, with all related derivative positions reported as 0 remaining after the merger.
Day One Biopharmaceuticals’ General Counsel & Secretary Adam Dubow disposed of all reported equity holdings in connection with the company’s cash merger. On the April 23, 2026 closing of the merger with Servier, each share of common stock was purchased or converted into the right to receive $21.50 in cash per share, subject to taxes.
The filing shows 72,694 shares of common stock and multiple grants of restricted stock units and stock options reported as dispositions to the issuer. Footnotes state that unvested stock options and RSUs became fully vested immediately before the merger, then were canceled for cash based on the $21.50 merger consideration (less the applicable exercise price for options). After these transactions, the form reports zero shares and zero derivatives remaining for the reporting person.
Day One Biopharmaceuticals director Natalie C. Holles reported the cash-out of all remaining equity awards in connection with the Servier acquisition. On April 23, 2026, her 57,310 shares of common stock, 15,000 restricted stock units, and multiple stock option grants were disposed of to the issuer at the merger closing.
Under the merger completed at an Offer Price of $21.50 per share, each common share was purchased or converted into the right to receive cash, and each stock option and RSU was canceled for a cash payment based on the merger consideration, less any required taxes. Following these transactions, the Form 4 shows no remaining common stock or derivative holdings for Holles.